Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
10Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Olema Pharmaceuticals, Inc. (OLMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
4Distinct source URLs
7High confidence
0.755Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Olema Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
KR-OYSTER-POINT-II-LLC
KR-OYSTER-POINT-II-LLC
92%
The Company entered into a lease agreement with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an aggregate of approximately …
PFIZER-INC
PFIZER-INC
92%
Under the terms of the 2025 Pfizer Agreement, we are responsible for conducting the clinical trial for the combined therapies and Pfizer is responsible for supplying atirmociclib to us at no cost.
NOVARTIS-INSTITUTES-FOR-BIOMEDICAL-RESEARCH-INC
NOVARTIS-INSTITUTES-FOR-BIOMEDICAL-RESEARCH-INC
90%
The October 2023 Amendment No. 1 expanded the size of the ongoing ribociclib and palazestrant study cohort to a total of approximately 60 patients.
AURIGENE
AURIGENE
80%
Payments due to Aurigene upon or subsequent to regulatory approval will be accrued as a provision to cost of sales in the period when achievement of respective milestone target is probable
Reciprocal relationship from AZN graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from AZN grap…
of product candidates that we develop as viable treatment options; o addressing any competing technological and market developments; o negotiating favorable terms in any collaboration, licensing or o…
Reciprocal relationship from NVSEF graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from OLMA graph: . In June 2025, the Company exerc…
. In June 2025, the Company exercised its option to extend the lease term by an additional year, resulting in a revised expiration date of December 31, 2026 . The modification was accounted under ASC…
CAMBRIDGE-MASSACHUSETTS-OLEMA-ONCOLOGY-AUSTRALIA
CAMBRIDGE-MASSACHUSETTS-OLEMA-ONCOLOGY-AUSTRALIA
62%
complex since the information necessary to estimate the accruals is accumulated from the CROs and the Company's assessment of that information is subject to variability and uncertainty. In addition, …
COMPANY-LLC
COMPANY-LLC
62%
y is subject to risks and uncertainties common to late-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates…
KR-OYSTER-POINT-II-LLC
KR-OYSTER-POINT-II-LLC
62%
. The modification was accounted under ASC 842, resulting in a remeasurement of the lease liability and a corresponding $ 0.1 million increase to the ROU asset. The incremental borrowing rate was als…
NOVARTIS-PHARMA-AG
NOVARTIS-PHARMA-AG
62%
. In June 2025, the Company exercised its option to extend the lease term by an additional year, resulting in a revised expiration date of December 31, 2026 . The modification was accounted under ASC…
NVS
Novartis AG
62%
Reciprocal relationship from NVS graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from NVS graph: Reciprocal relationship from OLMA graph: . In June 2025, the Company exercised…
PRESENTATION-OLEMA-PHARMACEUTICALS-INC
PRESENTATION-OLEMA-PHARMACEUTICALS-INC
62%
complex since the information necessary to estimate the accruals is accumulated from the CROs and the Company's assessment of that information is subject to variability and uncertainty. In addition, …
Olema Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OLMA-DEBT-11506
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
OLMA-DEBT
Debt stack $4.0M
90%
Market cache reports total debt of $4.0M.
Olema Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Olema Pharmaceuticals, Inc..
Olema Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
OLMA-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 202 tracked holders.
Olema Pharmaceuticals, Inc. Extended Supply Chain Network
